[
  {
    "ts": null,
    "headline": "Vertex to Announce Third Quarter 2025 Financial Results on November 3rd",
    "summary": "BOSTON, October 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Third Quarter 2025 Earnings Call.\"",
    "url": "https://finnhub.io/api/news?id=daf86fa1ee9abe8c2363c8902e986f5b363d9f1af6a2e5a96178fef8fd61ab63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759780800,
      "headline": "Vertex to Announce Third Quarter 2025 Financial Results on November 3rd",
      "id": 136999296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, October 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Third Quarter 2025 Earnings Call.\"",
      "url": "https://finnhub.io/api/news?id=daf86fa1ee9abe8c2363c8902e986f5b363d9f1af6a2e5a96178fef8fd61ab63"
    }
  },
  {
    "ts": null,
    "headline": "What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities continued their upward journey in the third quarter with the S&P 500 Index surging 8.1% and tech-heavy Nasdaq Composite rising 11.2% to record highs. Investor optimism was driven […]",
    "url": "https://finnhub.io/api/news?id=5603913810e55577f93db044ba3c15d8b9b17e6ab086491e06272b8793674bf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757958,
      "headline": "What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?",
      "id": 136989645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities continued their upward journey in the third quarter with the S&P 500 Index surging 8.1% and tech-heavy Nasdaq Composite rising 11.2% to record highs. Investor optimism was driven […]",
      "url": "https://finnhub.io/api/news?id=5603913810e55577f93db044ba3c15d8b9b17e6ab086491e06272b8793674bf6"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=abccda4bdc6cd6769971fad434c2c10bdb3d21b8e80cd1c58203baf5f7e72ba8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755604,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 136989646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=abccda4bdc6cd6769971fad434c2c10bdb3d21b8e80cd1c58203baf5f7e72ba8"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics Appoints Smith as Permanent CEO",
    "summary": "Stoke Therapeutics Appoints Smith as Permanent CEO",
    "url": "https://finnhub.io/api/news?id=8fc245a3cf62f39957609ec92fc1cf62d62c9fadcaea7ef1aeb87ce8eb0e5fd3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759747080,
      "headline": "Stoke Therapeutics Appoints Smith as Permanent CEO",
      "id": 137080675,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Stoke Therapeutics Appoints Smith as Permanent CEO",
      "url": "https://finnhub.io/api/news?id=8fc245a3cf62f39957609ec92fc1cf62d62c9fadcaea7ef1aeb87ce8eb0e5fd3"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock with Exciting Potential and 2 Facing Challenges",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.",
    "url": "https://finnhub.io/api/news?id=2d4f4c64861ab1288967f6a6fcfe31f3dd08f2dddd748dcccbf5d560c66c7040",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759725756,
      "headline": "1 Healthcare Stock with Exciting Potential and 2 Facing Challenges",
      "id": 136989647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.",
      "url": "https://finnhub.io/api/news?id=2d4f4c64861ab1288967f6a6fcfe31f3dd08f2dddd748dcccbf5d560c66c7040"
    }
  }
]